Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Historical Holders from Q4 2020 to Q3 2025

Symbol
COGT on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
160,377,960
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
159,214,681
Holdings value
$2,286,257,324
% of all portfolios
0.011%
Number of holders
190
Number of buys
122
Number of sells
-70
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% $81,355,047 16,569,256 FMR LLC 31 Dec 2024
Fairmount Funds Management LLC 9.9% 0% $224,347,916 +$21,936,825 15,877,418 +10.8% Fairmount Funds Management LLC 13 Nov 2025
Commodore Capital LP 7.2% +28.3% $146,587,742 +$54,568,000 10,208,060 +59.3% Commodore Capital LP 30 Sep 2025
Flynn James E 6.49% $65,023,115 9,053,118 Deerfield Mgmt, L.P. 07 Jul 2025
Kynam Capital Management, LP 5.54% $113,245,430 7,886,172 Kynam Capital Management, LP 30 Sep 2025
TCG Crossover GP I, LLC 4.8% $97,621,606 6,798,162 TCG Crossover GP I, LLC 30 Sep 2025
Point72 Asset Management, L.P. 4% -52.2% $82,625,042 -$60,775,814 5,753,833 -42.4% Point72 Asset Management, L.P. 30 Sep 2025
Venrock Healthcare Capital Partners II, L.P. 4.2% -26.7% $44,463,093 -$15,815,581 4,755,411 -26.2% Venrock Healthcare Capital Partners II, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 2.3% -75.6% $45,325,875 -$103,335,292 3,156,398 -69.5% Paradigm BioCapital Advisors LP 30 Sep 2025

Institutional Holders of Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 159,214,681 $2,286,257,324 +$377,674,083 $14.36 190
2025 Q2 135,519,487 $973,045,860 +$18,987,122 $7.18 175
2025 Q1 133,492,788 $799,614,961 +$57,857,622 $5.99 182
2024 Q4 121,716,056 $949,488,255 -$21,661,319 $7.8 173
2024 Q3 121,834,182 $1,316,352,629 +$470,587 $10.8 160
2024 Q2 121,381,737 $1,023,259,146 +$106,597,224 $8.43 146
2024 Q1 109,208,822 $733,878,161 +$128,257,287 $6.72 144
2023 Q4 90,814,821 $533,992,647 -$45,403,172 $5.88 141
2023 Q3 90,861,393 $885,844,189 +$20,538,646 $9.75 134
2023 Q2 88,529,694 $1,048,151,896 +$158,614,636 $11.84 134
2023 Q1 75,176,767 $810,346,243 +$3,226,883 $10.79 133
2022 Q4 74,675,712 $863,268,307 -$1,804,375 $11.56 133
2022 Q3 73,734,143 $1,100,096,408 +$70,755,840 $14.92 129
2022 Q2 70,081,829 $632,136,824 +$209,072,563 $9.02 107
2022 Q1 47,217,562 $353,580,440 -$5,659,624 $7.49 81
2021 Q4 44,899,168 $385,164,997 +$41,807,073 $8.58 80
2021 Q3 36,797,124 $309,606,147 +$4,142,169 $8.41 71
2021 Q2 34,971,040 $283,623,000 +$12,872,399 $8.11 65
2021 Q1 34,431,767 $303,253,000 +$9,820,126 $8.78 65
2020 Q4 33,524,756 $376,481,000 +$318,450,000 $11.23 67